Tyrosine kinase inhibitors (TKIs) and programmed cell death-1 (PD-1) inhibitors have demonstrated efficacy in managing ICC, highlighting their potential in expanding treatment options for this malignancy [7–9]. This evidence concerns the gene PDCD1 and intrahepatic cholangiocarcinoma.